SD
Swati Dattatray Kurandale
About Swati Dattatray Kurandale
Data last updated:
Swati Dattatray Kurandale is a Director at Ardent Clinical Research Services Private Limited (since 2024) and Director at St Source Transcript Private Limited (since 2024). The companies operate in Travel and Hospitality and Software. The largest current company by reported revenue is Ardent Clinical Research Services Private Limited at ₹84 Lakh (FY 2025).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
 Ardent Clinical Research Services Private Limited U85300TG2021PTC154680 | Director | 20 Sep 2024 | 2021 | ₹84 Lakh (FY 2025) | Active |
 St Source Transcript Private Limited U72200PN2024PTC236024 | Director | 28 Nov 2024 | 2024 | Active |
Board colleagues of Swati Dattatray Kurandale
| Name | DIN | Company | Designation |
|---|---|---|---|
| Chandu Gangadhar Devanpalli | 09308822 | Ardent Clinical Research Services Private Limited , St Source Transcript Private Limited | Director |
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Swati Dattatray Kurandale
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Swati Dattatray Kurandale
Swati Dattatray Kurandale currently holds 2 directorships: Ardent Clinical Research Services Private Limited (Director, since 20 Sep 2024, revenue ₹84 Lakh (FY 2025)); St Source Transcript Private Limited (Director, since 28 Nov 2024).
Swati Dattatray Kurandale was first appointed on 20 Sep 2024 as Director at Ardent Clinical Research Services Private Limited.
The current boards of Swati Dattatray Kurandale's companies include Chandu Gangadhar Devanpalli (Ardent Clinical Research Services Private Limited).